ALLO

Conviction 27HealthcareScan · Thu, Sep 24, 2026

Allogene Therapeutics, Inc. (ALLO) closed at $1.66 (-0.60%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 35, RS Rating 81, -45.8% from its 52-week high, +23.0% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

ALLO$1.66-0.60%

ResistanceSupportVol 14Insider sell

Vol MA14 6.31M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Allogene Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.allogene.com ↗

Price1.66

Change-0.60%

Gap-0.30%

Rel volume1.71×

Avg volume5.77M

Avg $ vol10.39M

SMA 201.82

SMA 501.90

SMA 2001.99

Price vs 50-12.58%

Price vs 200-16.59%

MA stackbearish

50/200 cross—

Supertrenddown · 1.94

RSI (14)35

MACD hist-0.01

MACD cross—

Stoch %K / %D15 / 13

ADX (14)24

+DI / −DI12 / 29

RSI divergence—

MACD divergenceBullish

ATR %5.90%

ADR %4.87%

52w high3.06

52w low1.05

From 52w high-45.75%

Above 52w low+58.10%

New 52w highNo

SqueezeOff

Bollinger width30.66%

%B0.21

Donchian pos11.11%

Donchian high2.14

Donchian low1.60

AVWAP (52w high)2.19

vs AVWAP high-24.19%

AVWAP (52w low)2.10

vs AVWAP low-21.11%

OBV trendDown

Chaikin MF (20)-0.20

Today vs 20d1.71×

Avg vol (14d)6.31M

Avg vol (20d)5.77M

Avg $ vol (20d)10.39M

Market cap573.51M

RS Rating81 / 99

RS 3m (vs SPY)-23.91%

RS 6m (vs SPY)-45.57%

RS line new highNo

Trend template3/8

Technical rank15.3

1 week-4.05%

1 month-23.50%

3 months-19.42%

6 months-28.76%

1 year+41.88%

YTD+22.96%

P/E-3.00

P/B1.31

P/S—

P/FCF-3.83

EPS-0.8700

Div yield—

ROE-43.76%

ROA-34.70%

Debt/Eq—

Current10.72

EV/EBITDA-2.72

Gross margin—

Net margin—

Rev growth-100.00%

EPS growth25.90%

Price target10.25

Target upside517.47%

Analyst ratingBuy

Institutional88.34%

Ent. value534.89M

Revenue4.64M

Net income-42.68M

Gross profit—

Free cash flow-149.63M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out345.15M

Employees152

ListedThu, Oct 11, 2018

Free float169.95M

Float %69.4%

Short interest59.11M

Days to cover12.2d

Short volume69.2%

Squeeze score95 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.13 vs −$0.16

Last surprise+18.8% beat

Setup gradeD

Conviction27 / 100

Pattern quality—

Tech rank15.3 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.22

Support1.65

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ALLO

All disclosures →

No recent disclosed trades by Congress in ALLO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ALLO · open-market 2 sells

Insider	Side	Shares	Value	Traded	Filed
Douglas Earl Martin SVP, General Counsel · Common Stock · 2026-08-21	Sell	29.7K	$63K	2026-08-21	2026-08-25
Roberts Zachary President and CEO · Restricted Stock Unit · 2026-07-01	Grant	134.53K	—	2026-07-01	2026-07-06
Roberts Zachary President and CEO · Stock Option (Right to buy) · 2026-07-01	Grant	476.19K	—	2026-07-01	2026-07-06
Yoshiyama Annie SVP, Finance · Common Stock · 2026-04-21	Sell	9.59K	$22K	2026-04-21	2026-04-23

SEC filings

EDGAR filings in ALLO · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.